[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100598931":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":34,"responsibleParty":81,"collaborators":83,"id":87,"slug":88,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":20,"eligibilityCriteria":93,"healthyVolunteers":89,"sex":94,"minAge":95,"maxAge":96,"enrollmentInfo":97,"targetDuration":20,"studyType":100,"phases":101,"briefSummary":103,"conditions":104,"keywords":106,"overallStatus":37,"whyStopped":20,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},{"fullName":5,"class":6},"Tulane University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"HS patients arm","EXPERIMENTAL","Patients must have a diagnosis of HS based upon the clinical criteria of a history of more or equal than 5 typical lesions (erythematous papules, nodules, or abscesses) in flexural sites with a recurring nature over time.\n\nPatients must be candidate for topical therapy defined by active Hurley stage I or Hurley stage II\u002FIII with active disease after an adequate trial of systemic antibiotics\u002Fhormonal\u002Fimmunomodulatory or biologic therapy.",[13],"Drug: Topical roflumilast 0.3% foam",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Topical roflumilast 0.3% foam","Topical roflumilast is a potent phosphodiesterase 4 (PDE4) inhibitor approved for the treatment of psoriasis, seborrheic dermatitis and atopic dermatitis",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Carole Bitar, MD","PRINCIPAL_INVESTIGATOR",[26,30],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","504-988-5114","cbitar@tulane.edu",{"name":31,"role":27,"phone":32,"phoneExt":20,"email":33},"Edward Coleman, MS","504-988-5135","ecoleman@tulane.edu",[35,52,64,73],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Lakeview Hospital","RECRUITING","Covington","Louisiana","70433","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-90.10042,30.47549,{"lat":47,"lon":46},[50,51],{"name":23,"role":27,"phone":20,"phoneExt":20,"email":20},{"name":23,"role":24,"phone":20,"phoneExt":20,"email":20},{"facility":53,"status":37,"city":54,"state":39,"zip":55,"country":41,"countryCode":42,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"Lakeside Hospital","New Orleans","70001",{"type":44,"coordinates":57},[58,59],-90.07507,29.95465,{"lat":59,"lon":58},[62,63],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},{"name":23,"role":24,"phone":20,"phoneExt":20,"email":20},{"facility":65,"status":37,"city":54,"state":39,"zip":66,"country":41,"countryCode":42,"cosmosGeoPoint":67,"geoPoint":69,"contacts":70},"LCMC Multi-speciality Clinic","70112",{"type":44,"coordinates":68},[58,59],{"lat":59,"lon":58},[71,72],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},{"name":23,"role":24,"phone":20,"phoneExt":20,"email":20},{"facility":74,"status":37,"city":54,"state":39,"zip":66,"country":41,"countryCode":42,"cosmosGeoPoint":75,"geoPoint":77,"contacts":78},"University Medical Center",{"type":44,"coordinates":76},[58,59],{"lat":59,"lon":58},[79,80],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},{"name":23,"role":24,"phone":20,"phoneExt":20,"email":20},{"type":82,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[84],{"name":85,"class":86},"Arcutis Biotherapeutics, Inc.","INDUSTRY","100598931","phase-2-a-study-for-evaluating-safety--efficacy-of-topical-roflumilast-03-foam-in-hidradenitis-suppurativa-100598931",false,"NCT07077902","A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa","An Open Label Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam as a Mono or add-on Therapy in the Treatment of Hidradenitis Suppurativa With Correlative Analysis.","Inclusion Criteria:\n\n* Must understand the risks and the benefits\u002Fpurpose of the study and provide signed and dated informed consent.\n* Must be 18 years at time of signing informed consent form.\n* Willing to participate in all required evaluations and procedures in the study including the ability to apply topical medication without difficulty.\n* Patients must have a diagnosis of HS based upon the clinical criteria of a history of more than or equal 5 typical lesions (erythematous papules, nodules, or abscesses) in flexural sites with a recurring nature over time.\n* Patients must be candidate for topical therapy defined by active Hurley stage I or Hurley stage II\u002FIII with active disease after an adequate trial of systemic antibiotics\u002Fhormonal\u002Fimmunomodulatory or biologic therapy.\n* Patient is required to be on stable dose of concomitant therapy for at least 3 months before enrollment and throughout the study period.\n* Females of childbearing potential must have a negative urine pregnancy test at baseline visit and be on adequate contraception throughout the study time.\n\nExclusion Criteria:\n\n* Concomitant use of topical antibiotics, topical corticosteroids, resorcinol, benzoyl peroxide, vitamin D analogs, Hibiclens wash (except for emollients) within 1 week of enrollment.\n* Increasing or changing dosing for concurrent therapy agents within 90 days before study day 0 and during the study period.\n* History of any clinically significant (as determined by the investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic, or other major uncontrolled disease.\n* Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he\u002Fshe were to participate in the study or confounds the ability to interpret data from the study.\n* Pregnant or breastfeeding.\n* Prior major surgery or major life-threatening medical illness within 2 weeks.\n* Active hepatitis B or C infection with detectible viral nucleic acid in the blood or known Human Immunodeficiency Virus (HIV) positivity.\n* Patients with known active malignancy.\n* Any severe systemic illness requiring Intravenous (IV) antibiotics within the two weeks prior to initiation of the study drug.\n* Active substance abuse or a history of substance abuse within 6 months prior to screening.\n* Use of any investigational drug within 4 weeks prior to randomization, or 5 pharmacokinetic\u002Fpharmacodynamic half-lives, if known (whichever is longer).","ALL","18 Years","90 Years",{"count":98,"type":99},10,"ESTIMATED","INTERVENTIONAL",[102],"PHASE2","This is a phase 2a, open label study.\n\nAs psoriasis and Hidradenitis Suppurativa (HS) share multiple inflammatory pathways, the investigators hypothesize that the use of topical roflumilast 0.3% foam is a safe and efficacious option as a monotherapy for patients with mild disease and as add-on therapy for maintenance and flares in patients with moderate to severe disease. The study will include correlative analysis to study gene expression profiling before and after therapy.",[105],"Hidradenitis Suppurativa",[107,108,109],"Topical roflumilast","Inflammatory skin condition","Painful nodules and abscesses in axilla and groin","2025-12-19",{"date":112,"type":113},"2025-12-23","ACTUAL",{"date":115,"type":113},"2025-09-25",{"date":117,"type":99},"2026-09",{"name":5,"class":6},4]